CTLA4 and neoplasm: Currently, a first clinical CTLA-4 imaging study is ongoing, where tumor lesion uptake and biodistribution of 89Zr-labeled ipilimumab will be assessed at the start of ipilimumab therapy and 3 weeks post start of therapy.